Clinical trials: Macular Diseases, active
Neovascular (Wet) Age-Related Macular Degeneration
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual…
- Trial name
- NCT07390253
- Testing
- Aflibercept
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
Low Vision, Central Visual Impairment
Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss
Central vision loss from macular degeneration creates blind spots that impair reading, face recognition, and navigation. Individuals must learn to use peripheral vision, requiring retraining of eye movements.
- Conditions
- Low Vision, Central Visual Impairment, Macular Degeneration
- Trial name
- NCT07577219
- Testing
- eccentric viewing training with biofeedback
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New England College of Optometry
Age Related Macular Degeneration, Geographic Atrophy
Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD.
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy, AMD, Age-related Macular Degeneration
- Trial name
- Project AMD (NCT04739319)
- Testing
- N/A Observational study
- Where
- Australia
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Age Related Macular Degeneration (AMD)
Development of Novel Clinical Endpoints in Intermediate AMD
Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) - MACUSTAR
- Trial name
- MACUSTAR (NCT03349801)
- Testing
- No intervention
- Where
- 20 sites in Denmark, France and 5 more
- Volunteers
- 718 people, healthy volunteers welcome
- Sponsor
- Frank G. Holz
Geographic Atrophy, Age - Related Macular Degeneration (AMD)
An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy
The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2)…
- Trial name
- NCT07705568
- Testing
- PST-611
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Eyevensys
Age-Related Macular Degeneration
Impact of Age-related Macular Degeneration on Daily Living Activitie
The complex and variable course of age-related diseases makes it all the more necessary to carry out personalised, reasoning-based examinations to improve the personalised assessment and management of AMD.
- Trial name
- AMDAY (NCT06333873)
- Testing
- patient-reported outcome
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Age-Related Macular Degeneration (ARMD)
Can the Risk for AMD be Modulated?
The goal of this Cross-sectional, interventional study is to learn about whether different risk factors, as Mediterranean diet, lifestyle and concomitant medication can modulate the risk imprinted by genetics in Age-related…
- Trial name
- AMD_LifeGene (NCT05735730)
- Testing
- Blood draw
- Where
- Portugal
- Volunteers
- 1,800 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Geographic Atrophy
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant.
- Trial name
- PRIMAvera (NCT04676854)
- Testing
- PRIMA Bionic Vision System
- Where
- 21 sites in France, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Science Corporation
Cataract, Intraocular Lens Complication
Functional IOL Implantation in Patients With Epiretinal Membrane
We have designed this prospective study to evaluate macular involvement and epiretinal membrane (ERM) grading by OCT in eyes with ERM and to compare clinical outcomes after implantation of Enhance IOL with standard monofocal IOL…
- Conditions
- Cataract, Intraocular Lens Complication, Epiretinal Membrane
- Trial name
- NCT06719739
- Testing
- Intraocular lens implantation
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Intermediate AMD
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect.
- Trial name
- retinaSEES-PoC (NCT06557369)
- Testing
- reSEES
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Oculox Technologies SA
Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy
- Trial name
- HANGANG (NCT07461441)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Dry Age-related Macular Degeneration, Macular Degeneration, Dry
Observation of the Natural Course of Age-related Macular Degeneration
This research will study natural course of dry AMD in Chinese population, screen fundus imaging indicators for patients with Chinese dry AMD, describe the clinical features of Chinese patients with dry AMD, and obtain a…
- Trial name
- NCT05418231
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Macular Degeneration, Age Related
Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material
Whose aim is to: Determine the percentage of patients with resolution of subretinal hyperreflective material (SHRM) at week 16. This study is intended to be performed in the ophthalmology departments or ophthalmology clinics of…
- Trial name
- NCT07403825
- Testing
- Vabysmo 6 MG in 0.05 ML Injection
- Where
- 10 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Biobizkaia Health Research Institute
Hypopigmentation
Characterization of Bacterial and Mycosis Skin Flora in Seborrheic Macular Hypopigmentation - Microbiome
Hypopigmented skin changes are commonly encountered by dermatologists. A new dermatological entity was identified as scattered, hypopigmented oval-shaped macules and patches distributed mostly in seborrheic area of the face and…
- Trial name
- Microbiome_SHM (NCT06908889)
- Testing
- Skin's lesion patients, Skin's lesion vulunteers
- Where
- 3 sites in France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
Diabetes mellitus is a disorder of sugar and fat metabolism which results in damage to the small blood vessels in various organs, this includes the retina - the part of the eye that processes light into a nerve impulse.
- Conditions
- Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus, Diabetic Macular Edema (DME)
- Trial name
- IMLADRIS (NCT06914778)
- Testing
- Blood draw for the laboratory assessment, Urine sample
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hywel Dda Health Board
Extensive Macular Atrophy With Pseudodrusen (EMAP), Retinitis Pigmentosa (RP)
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases
his prospective, comparative pilot study investigates the safety and functional outcomes of subtenon autologous platelet-rich plasma (PRP) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with…
- Trial name
- RETINA-PRP (NCT07341919)
- Testing
- Subtenon Injection of Autologous Platelet-Rich Plasma
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Rubens Camargo Siqueira
Exudative Macular Degeneration
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and…
- Trial name
- NCT05093374
- Testing
- anti-VEGF agent
- Where
- Austria
- Volunteers
- 290 people
- Sponsor
- Medical University of Vienna
Dry Age-related Macular Degeneration, Geographic Atrophy
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
- Trial name
- PATCH-AMD (NCT06557460)
- Testing
- Surgical implantation of the CPCB-RPE1 implant
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regenerative Patch Technologies, LLC
Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration
Changes in Intraocular Pressure After Intravitreal Injection
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP).
- Conditions
- Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, Retinal Vein Occlusion, Ocular Hypertension
- Trial name
- NCT07826286
- Volunteers
- 50 people
- Sponsor
- Assiut University